Sanofi: Barclays upgrades stock thanks to Dupixent
(CercleFinance.com) - On Monday Barclays upgraded Sanofi shares from "equal weight" to "overweight", following "impressive" clinical results that it unveiled last week for Dupixent in the treatment of COPD.
In a study of the European pharmaceutical sector, the analyst now expects annual sales of E22bn for Dupixent by 2030, up from a previous forecast of E16.5bn.
The broker says that this development highlights the value side of the Sanofi stock, i.e. its low valuation compared to other stocks such as GSK and Novartis.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
In a study of the European pharmaceutical sector, the analyst now expects annual sales of E22bn for Dupixent by 2030, up from a previous forecast of E16.5bn.
The broker says that this development highlights the value side of the Sanofi stock, i.e. its low valuation compared to other stocks such as GSK and Novartis.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.